A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

Journal of Clinical Oncology

Volumn 10, Issue 2, 1992, Pages 257-263

  Jacobs, Charlotte ^b   Lyman, Gary ^b   Velez García, Enríque ^b   Sridhar, Kasi S ^b   Knight, William ^b   Hochster, Howard ^b   Goodnough, Lawrence T ^b   Mortimer, Joanne E ^b   Einhorn, Lawrence H ^b   Schacter, Lee ^a   Cherng, Nehemiah ^b   Dalton, Traci ^b   Burroughs, Jim ^b   Rozencweig, Marcel ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CONTROLLED STUDY; DIARRHEA; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; OTOTOXICITY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; VOMITING;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMPARATIVE STUDY; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMAN; MALE; MIDDLE AGE; NEOPLASM RECURRENCE, LOCAL; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS;

EID: 0026569931     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1992.10.2.257     Document Type: Article

References (33)

1. American Cancer Society: Cancer Facts, Figures 1990. Atlanta, GA, American Cancer Society, 1990
2. Wheeler RH: Chemotherapy of patients with recurrent head and neck cancers, in Jacobs C (ed): Carcinomas of the Head and Neck: Evaluation, Management. Boston, MA, Kluwer Academic, 1990. pp 171-193
3. Hong WK, Schaefer S, Issell B, et al: A prospective random-ized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer 52:206-210, 1983
4. Tapazoglou E, Kish J, Ensley J, et al: The activity of a single agent 5-fluorouracil infusion in advanced and recurrent head and neck cancer. Cancer 57:1105-1109, 1986
5. Havlin KA, Kuhn JG, Myers JW, et al: High-dose cisplatin for iocally advanced or metastatic head and neck cancer: A phase II pilot study. Cancer 63:423-427, 1989
6. Eisenberger MA, Hornedo J, Silva H, et al: Carboplatin (NSC-241-240) an active platinum analog for the treatment of squamous cell carcinoma of the head and neck. J Clin Oncol 4:1506-1509, 1986
7. Robert F: Trimetrexate as a single agent in patients with advanced head and neck cancer. Semin Oncol 15:22-26, 1988 (suppl 2)
8. Jacobs C, Meyers F, Hendrickson C, et al: A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck. Cancer 52:1563-1569, 1983
9. Vogl SE, Schoenfeld DA, Kaplan BH, et al: A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer. Cancer 56:432-442, 1985
10. Eisenberger M, Krasnow S, Ellenberg S, et al: A comparison of carboplatin plus methotrexate versus methotrexate alone in patients with recurrent and metastatic head and neck cancer. J Clin Oncol 7:1341-1345, 1989
11. Campbell JB, Dorman EB, McCormick J, et al: A randomized phase III trial of cisplatinum, methotrexate, cisplatinum + methotrexate, and cisplatinum + fluorouracil in end-stage head and neck cancer. Acta Otolaryngol 103:519-528, 1987
12. Clavel M, Cappelare P, Cognetti F, et al: Comparison between C (cisplatin) alone, two cisplatin containing multiple drug regimens: CABO (cisplatin, methotrexate, bleomycin, oncovin), and CF (cisplatin-FU) in advanced head and neck carcinomas. Report on a randomized EORTC trial 24842 including 380 patients. Cancer Chemother Pharmacol, 23:c73, 1989 (suppl 2; abstr A292)
13. The Liverpool Head and Neck Oncology Group: A phase III randomized trial of cisplatinum, methotrexate, cisplatinum + methotrexate and cisplatinum + 5FU in end stage squamous carcinoma of the head and neck. Br J Cancer 61:311-315, 1990
14. Kish JA, Weaver A, Jacobs J, et al: Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 53:1819-1824, 1984
15. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288.1984
16. Cox DR, Snell ES: Analysis of Binary Data, ed 2. London, UK, Chapman and Hall, 1989, p 13
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
18. Peto R, Peto J: Asymptotically efficient rank invariant procedure. J R Stat Soc [A] 135:185-206, 1972
19. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980
20. Cox DR: Regression models and life tables. J R Stat Soc [B] 34:187-220, 1972
21. Mercier RJ, Neal GD, Mattox DE, et al: Cisplatin and 5-fluorouracil chemotherapy in advanced or recurrent squamous cell carcinoma of the head and neck. Cancer 60:2609-2612, 1987
22. Rowland KM Jr, Taylor SG, Spiers AS, et al: Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: An Eastern Oncology Group pilot study. Cancer Treat Rep 70:461-464, 1986
23. Larson JT, Adams GL, Fattah HA: Survival statistics for multiple primaries in head and neck cancer. Otolaryngol Head Neck Surg 103:14-24, 1990
24. Morton RP, Stell PM: Cytotoxic chemotherapy for patients with terminal squamous carcinoma - Does it influence survival? Clin Otolaryngol 9:175-180, 1984
25. Amer MH, Al-Sarraf M, Vaitkevicius VK: Factors that affect response to chemotherapy and survival of patients with advanced head and neck cancer. Cancer 43:2202-2206, 1979
26. Bertino JR, Boston B, Capizzi RL: The role of chemotherapy in the management of cancer of the head and neck: A review. Cancer 36:752-758, 1975
27. Stanley KE: Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65:25-32, 1980
28. Ensley JF, Kish JA, Weaver AA, et al: The correlation of specific variables of tumor differentiation with response rate and survival in patients with advanced head and neck cancer treated with induction chemotherapy. Cancer 63:1487-1492, 1989
29. Cooke LD, Cooke TG, Bootz G, et al: Ploidy as a prognostic indicator in end stage squamous cell carcinoma of the head and neck region treated with cisplatinum. Br J Cancer 61:759-762, 1990
30. Dodwell DJ, Gurney H, Thatcher N: Dose intensity in cancer chemotherapy. Br J Cancer 61:789-794, 1990
31. Paredes J, Hong WK, Felder TB, et al: Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 6:955-962, 1988
32. Veronesi A, Zagonel U, Tirelli E, et al: High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: A randomized study. J Clin Oncol 3:1105-1108, 1985
33. Kish JA, Ensley JF, Jacobs J, et al: A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer 56:2740-2744, 1985